Mass spectrometry-based antigen discovery for cancer immunotherapy

Highlights • Immunopeptidomics analysis reveals the in vivo antigenic repertoire of tumors. • Shared cancer antigens and private neo-epitopes are detected by immunopeptidomics. • Reactive T cells recognizing neo-epitopes are present in tumor and blood of cancer patients. • Discovery of neo-epitopes by MS-based immunopeptidomics is fast and cost-effective. • This approach can guide development of T cell-based therapies and vaccines.